ArticleEuropean journal of medical research2025
Myeloid dendritic cells in peripheral blood correlate with the occurrence of acute graft-versus-host disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute graft-versus-host disease (aGVHD) remains a life-threatening complication that limits the efficacy and application of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early identification and diagnosis of aGVHD is significant for improving the outcomes of allo-HSCT. We retrospectively analyzed the dendritic cell (DC) subsets in peripheral blood (PB) of patients who received allo-HSCT before transplantation and at engraftment to evaluate the correlation between DC subsets and the occurrence of aGVHD. The results showed that the proportion and count of myeloid dendritic cells (mDCs) before transplantation were positively correlated with the occurrence and severity of aGVHD, while the proportion and count of mDCs at engraftment were negatively correlated with those. In addition, patients with higher proportion and count of mDCs before transplantation developed aGVHD earlier, whereas those without aGVHD had the lowest proportion and count of mDCs before transplantation. The proportions and counts of DC subsets at engraftment were not significantly correlated with the onset time of aGVHD. Receiver operating characteristic (ROC) curve analysis demonstrated that the count of mDCs in PB before transplantation had greater sensitivity and specificity in predicting aGVHD (AUC = 0.8002, P < 0.0001) compared to plasmacytoid DCs (pDCs) and total DCs. Multivariate logistic regression analysis confirmed that the count of mDCs in PB before transplantation and at engraftment were independent factors in predicting the occurrence of aGVHD (OR = 9.907, P = 0.018, 95% CI 1.473-66.639; OR = 0.059, P = 0.023, 95% CI 0.005-0.673). Therefore, mDCs in PB play an important role in the development of aGVHD and may serve as a promising predictor of aGVHD for patients undergoing allo-HSCT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.